The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis

Oliveira, Vanessa De; Mahajan, Nitin; Bates, Melissa L.; Tripathi, Chakrapani; Kim, Kyusik Q.; Zaher, Hani; Maggi, Leonard B.; Tomasson, Michael H.

doi:10.1096/fba.2018-00075

Cited by 17 publications

(13 citation statements)

References 39 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ST798; Beyotime Institute of Biotechnology) for 3 min at room temperature. The cells were counted using a haemocytometer under an inverted microscope (CKX53; Olympus Corporation) and cells that were observed to exclude the dye were considered viable, as described previously ( 13 ).…”

Section: Methodsmentioning

confidence: 99%

Role of vasodilator‑stimulated phosphoprotein in RANKL‑differentiated murine macrophage RAW264.7 cells: Modulation of NF‑κB, c‑Fos and NFATc1 transcription factors

Zhang

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Vasodilator-stimulated phosphoprotein (VASP) is essential for osteoclast differentiation, and reduced VASP expression results in depressed osteoclast differentiation. Previously, we demonstrated the importance of VASP and Ras-related C3 botulinum toxin substrate 1 interactions in osteosarcoma cell migration and metastasis using Mg-63 and Saos2 cells. However, the molecular details of the functional role of VASP in cell motility and migration remain to be elucidated. The present study demonstrated that VASP affects the expression of αV-integrin, tartrate-resistant acid phosphatase (TRAP) and lamellipodia protrusion in RAW 264.7 murine macrophage cells. The RAW 264.7 mouse monocyte macrophage cell line was used as an osteoclast precursor. RAW 264.7 cells were treated with 50 ng/ml of receptor activator of nuclear factor κ-Β ligand (RANKL) in order to induce cell differentiation (osteoclastogenesis). Small interfering RNA (siRNA) was used to silence VASP, and RT-PCR and western blotting were used to determine the expression for genes and proteins, respectively. TRAP staining as a histochemical marker for osteoclast and fluorescent microscopy for lamellipodia protrusion was performed. RANKL treatment significantly increased the gene and protein expression of VASP, αV-integrin and TRAP in RAW 264.7 cells. Silencing of VASP significantly reduced the RANKL-induced expression of αV-integrin, TRAP and lamellipodia protrusion. In addition, knockdown of VASP attenuated RANKL-stimulated activation of NF-κB, c-Fos and nuclear factor of activated T cells cytoplasmic 1 transcription factors, and the phosphorylation of the p65 and IκBα. These results suggest the critical role of VASP in regulating osteoclast differentiation, which should be further explored in osteosarcoma research.

show abstract

Section: Methodsmentioning

confidence: 99%

Role of vasodilator‑stimulated phosphoprotein in RANKL‑differentiated murine macrophage RAW264.7 cells: Modulation of NF‑κB, c‑Fos and NFATc1 transcription factors

Zhang

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…SnoRNAs are a class of small RNA molecules that mediate modifications of rRNAs, tRNAs, and snRNAs. The snoRNA ACA11 was overexpressed in multiple myeloma cells, increasing ROS and resulting in protein production and cell proliferation 174 . There are currently no reports on ferroptosis and snRNAs which mediate post-transcriptional splicing in gene expression.…”

Section: Introductionmentioning

confidence: 99%

Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression

Zhang

Wang

et al. 2020

Cell Death Dis

View full text Add to dashboard Cite

Cancer progression including proliferation, metastasis, and chemoresistance has become a serious hindrance to cancer therapy. This phenomenon mainly derives from the innate insensitive or acquired resistance of cancer cells to apoptosis. Ferroptosis is a newly discovered mechanism of programmed cell death characterized by peroxidation of the lipid membrane induced by reactive oxygen species. Ferroptosis has been confirmed to eliminate cancer cells in an apoptosis-independent manner, however, the specific regulatory mechanism of ferroptosis is still unknown. The use of ferroptosis for overcoming cancer progression is limited. Noncoding RNAs have been found to play an important roles in cancer. They regulate gene expression to affect biological processes of cancer cells such as proliferation, cell cycle, and cell death. Thus far, the functions of ncRNAs in ferroptosis of cancer cells have been examined, and the specific mechanisms by which noncoding RNAs regulate ferroptosis have been partially discovered. However, there is no summary of ferroptosis associated noncoding RNAs and their functions in different cancer types. In this review, we discuss the roles of ferroptosis-associated noncoding RNAs in detail. Moreover, future work regarding the interaction between noncoding RNAs and ferroptosis is proposed, the possible obstacles are predicted and associated solutions are put forward. This review will deepen our understanding of the relationship between noncoding RNAs and ferroptosis, and provide new insights in targeting noncoding RNAs in ferroptosis associated therapeutic strategies.

show abstract

“…Whether some clinical features, such as highly proliferative or extramedullary disease (EMD), should increase the inclination to administer alkylators is, as yet, unknown, although melflufen performed well in EMD patients [ 134 ]. Although some preclinical studies suggest biomarkers affecting response to alkylators [ 135 ], these data are so far too immature to impact treatment choice.…”

Section: Current Standard Of Carementioning

confidence: 99%

Current and Novel Alkylators in Multiple Myeloma

Schjesvold

Oriol

2021

Cancers

View full text Add to dashboard Cite

A large number of novel treatments for myeloma have been developed and approved; however, alkylating drugs continue to be part of standard regimens. Additionally, novel alkylators are currently being developed. We performed a non-systematized literary search for relevant papers and communications at large conferences, as well as exploiting the authors’ knowledge of the field, to review the history, current use and novel concepts around the traditional alkylators cyclophosphamide, bendamustine and melphalan and current data on the newly developed pro-drug melflufen. Even in the era of targeted treatment and personalized medicine, alkylating drugs continue to be part of the standard-of-care in myeloma, and new alkylators are coming to the market.

show abstract

The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis

Cited by 17 publications

References 39 publications

Role of vasodilator‑stimulated phosphoprotein in RANKL‑differentiated murine macrophage RAW264.7 cells: Modulation of NF‑κB, c‑Fos and NFATc1 transcription factors

Role of vasodilator‑stimulated phosphoprotein in RANKL‑differentiated murine macrophage RAW264.7 cells: Modulation of NF‑κB, c‑Fos and NFATc1 transcription factors

Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression

Current and Novel Alkylators in Multiple Myeloma

Contact Info

Product

Resources

About